Durvalumab Extends OS in NSCLC.
New data from the phase III PACIFIC trial of durvalumab in patients with stage III non-small cell lung cancer show that the drug increases the odds of surviving for 24 months. The study also confirms that progression-free survival and time to death or distant metastasis are longer for patients treated with durvalumab than for patients who received a placebo.